Bevacizumab (Avastin) IV Solution from Japan
Bevacizumab is a humanized monoclonal antibody blocking VEGF, used for colorectal and lung cancer. Under HTS 3002.15.00.11 for its role in immunological regulation via angiogenesis inhibition, in retail-measured vials.
Duty Rate — Japan → United States
15%
Rate breakdown
9903.04.6215%Pharmaceuticals: patented pharma from JP/EU/KR/CH/LI — 15% floor rate
9903.05.860%Universal product exemption (U.S. note 52(b))
9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)
Import Tips
• Include VEGF specificity test results and monoclonal purity assays in import docs
• Comply with USP <1079> for good distribution practices; avoid temperature excursions